SCHEMBL766972

SCHEMBL766972

C=C(C)c1ccccc1N1CCN(C(=O)C(=O)NC(C)(C)CO)CC1

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RBP4 P02753 6/20 0.43
MEN1 O00255 2/20 0.40
LMNA P02545 2/20 0.40
KMT2A Q03164 2/20 0.40
PAX8 Q06710 1/20 0.40
EED O75530 1/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 2/20 0.37
ENPP2 Q13822 3/20 0.37
MAPT P10636 3/20 0.37
ALDH1A1 P00352 2/20 0.37
PKM P14618 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
KDM4E B2RXH2 3/20 0.36
GLA P06280 2/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
P4HB P07237 1/20 0.36
USP2 O75604 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL767083 0.83 RBP4 (0.44) RBP4MEN1LMNAKMT2APAX8
SCHEMBL766151 0.82 RBP4 (0.66) RBP4
SCHEMBL10274111 0.79 RBP4 (0.50) RBP4MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL767464 0.73 RAB9A (0.39) RBP4LMNAKMT2ASMN1; SMN2TSHR
SCHEMBL10274552 0.72 GAA (0.43) RBP4MEN1KMT2AMAPTGAA
SCHEMBL10274548 0.71 RAB9A (0.48) RBP4MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL766973 0.69 NOTUM (0.46) RBP4MEN1KMT2ASMN1; SMN2TSHR
SCHEMBL767279 0.69 ALDH1A1 (0.43) MEN1KMT2AEEDSMN1; SMN2TSHR
SCHEMBL10274113 0.69 AKR1C3 (0.45) RBP4MEN1LMNAKMT2ASMN1; SMN2
SCHEMBL23735688 0.68 NPC1 (0.56) MEN1LMNAKMT2ASMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120071489-A1 DERIVATIVES OF N-ACYL-N'-PHENYLPIPERAZINE USEFUL (INTER ALIA) FOR THE PROPHYLAXIS OR TREATMENT OF DIABETES RBP4, RBP1, FABP4 RBP4 1/4885MEN1 3929/4885LMNA 1842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.